Roivant Sciences Ltd. (NASDAQ:ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the commencement of a proposed underwritten public offering of $150,000,000 of common shares. Roivant expects to grant the underwriter a 30-day option to purchase up to $22.5 million of additional common shares. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Roivant Sciences Announces $150M Proposed Public Equity Offering
Roivant Sciences Ltd. (NASDAQ:ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the commencement of a proposed underwritten public offering
Related Posts
Raymond James Maintains Strong Buy on Target, Raises Price Target to $200
Raymond James analyst Bobby Griffin maintains Target (NYSE:TGT) with a Strong Buy and raises the price target from $190 to $200.
Teamsters Unite Marijuana Workers Who Want Fair Share Of Missouri’s $1B Weed Revenue
Budtenders and inventory clerks at Home State Dispensary in Missouri have voted overwhelmingly to join Teamsters Local 955. They are the first group of cannabis workers in the Kansas City metropolitan area to unionize and the first to join Local 955.